Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy

The molecular events leading to gastroenteropancreatic neuroendocrine tumor (GEP-NET) formation are largely unknown. Over the past decades, systemic chemotherapies have been replaced by therapies directed at particular molecular targets such as the somatostatin receptors, mTOR complexes or proangiog...

Descripción completa

Detalles Bibliográficos
Autor principal: Crabtree, Judy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722794/
https://www.ncbi.nlm.nih.gov/pubmed/29255447
http://dx.doi.org/10.3389/fendo.2017.00341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722794/
https://www.ncbi.nlm.nih.gov/pubmed/29255447
http://dx.doi.org/10.3389/fendo.2017.00341

Ejemplares similares